Sharemaestro Newsreel

[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach …

U.K. regulator reaffirms safety of childhood vaccination

[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the …

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular …

InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001

IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation …

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline …

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT …

Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed

In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …

« Notre chiffre d’affaires devrait progresser d’environ 10 % en 2026 », Belén Garijo, la nouvelle dirigeante de Sanofi revoit à la hausse les prévisions du groupe et poursuit la revue du pipeline

Legrand, EssilorLuxottica et Michelin sur le podium gagnant du Cac 40 après leurs résultats, le changement de direction chez Sanofi passe mal

Sanofi affiche sa confiance pour 2026 après des résultats 2025 supérieurs aux attentes

Sanofi annonce un chiffre d’affaires de plus de 43 milliards d’euros en 2025

Sanofi présente de bons résultats, mais déçoit les investisseurs

Sanofi va racheter pour un milliard d’euros d’actions après des résultats solides

Sanofi : légère hausse après les résultats

De nouvelles statistiques américaines au programme pour attendre les résultats d'Apple, Sanofi, Eurofins Scientific et STMicro sur le gril en France

Prévisions Action Sanofi 2026–2030 | Perspectives

Prévisions action Sanofi : objectifs de prix tiers

Résultats de Sanofi : Une Forte Croissance des Bénéfices Soutient des Prévisions Optimistes pour l’Ensemble de l’Année

Sanofi dopé par Dupixent et ses nouveaux traitements, relève ses prévisions pour 2025

Résultats de Sanofi : notre estimation de la juste valeur est inchangée

Virbac: Prévisions et Estimations des Analystes | VIRP

Sanofi: Prévisions et Estimations des Analystes | SAN

Le prix de l'action Virbac SA (VIRP.PA) : Actualités et prévisions des analystes